Four Cycles Taxane With Trastuzumab and Pertuzumab Neoadjuvant Therapy Among Low Risk HER2 Positive Patients
NCT06722599
·
clinicaltrials.gov ↗
RECRUITING
Status
171
Enrollment
OTHER
Sponsor class
Conditions
HER2-positive Breast Cancer
Sponsor
Shu Wang